Kamada (KMDA) Liabilities and Shareholders Equity (2016 - 2026)
Kamada's (KMDA) quarterly Liabilities and Shareholders Equity came in at $383.2 million in Q2 2026, up 4.07% on a YoY basis from $368.2 million in Q2 2025, and little changed quarter-over-quarter from $383.0 million in Q1 2026.
Analysis
Kamada (KMDA) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
Kamada (KMDA) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $383.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 4.07% year-over-year to $383.2 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 3.77% YoY), and the FY2025 full-year result was $378.7 million, up 1.73% from the prior year.
- Liabilities and Shareholders Equity steadied at $383.2 million in Q2 2026 per KMDA's latest filing, from $383.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $383.2 million in Q2 2026 and bottomed at $303.1 million in Q1 2022.
- Historically, Liabilities and Shareholders Equity has averaged $347.5 million across 5 years, with a median of $351.1 million in 2024.
- The widest YoY moves for Liabilities and Shareholders Equity: up 47.62% in 2022, down 1.16% in 2022.
- Over 5 years, Liabilities and Shareholders Equity stood at $322.4 million in 2022, then advanced by 10.09% to $354.9 million in 2023, then gained by 4.89% to $372.3 million in 2024, then gained by 1.73% to $378.7 million in 2025, then advanced by 1.18% to $383.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $383.2 million, $383.0 million, and $378.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.30 Bn | 197.31 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 180.97 Bn | 177.79 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 132.27 Bn | 124.42 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 82.93 Bn | 74.93 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 61.53 Bn | 56.35 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 54.27 Bn | 49.13 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 34.46 Bn | 31.15 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.16 Bn | 29.88 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 30.08 Bn | 30.08 Bn | 1.16 Mn | 5.31 Bn |
| 10 | Kamada | 473.85 Mn | 403.72 Mn | 22.47 Mn | 383.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 383.16 Mn |
| Mar 31, 2026 | 383.02 Mn |
| Dec 31, 2025 | 378.71 Mn |
| Sep 30, 2025 | 377.21 Mn |
| Jun 30, 2025 | 368.17 Mn |
| Mar 31, 2025 | 375.11 Mn |
| Dec 31, 2024 | 372.26 Mn |
| Sep 30, 2024 | 351.21 Mn |
| Jun 30, 2024 | 351.04 Mn |
| Mar 31, 2024 | 343.17 Mn |
| Dec 31, 2023 | 354.91 Mn |
| Sep 30, 2023 | 337.06 Mn |
| Jun 30, 2023 | 314.39 Mn |
| Mar 31, 2023 | 316.80 Mn |
| Dec 31, 2022 | 322.38 Mn |
| Sep 30, 2022 | 319.64 Mn |
| Jun 30, 2022 | 304.14 Mn |
| Mar 31, 2022 | 303.10 Mn |
| Dec 31, 2021 | 318.67 Mn |
| Sep 30, 2021 | 216.53 Mn |